Skip to main content
. 2018 Aug 3;23(11):1349–1357. doi: 10.1634/theoncologist.2017-0692

Figure 3.

image

Cumulative incidences of clinical outcomes at 2 years after allo‐HSCT in MRD positive patients who received IFN‐α treatment and those who did not receive any interventions. (A) relapse; (B) nonrelapse mortality; (C) overall survival; and (D) disease‐free survival.

Abbreviations: IFN‐α, interferon‐α; MRD, minimal residual disease.